Updates are available Correction dated 2022-11-18
Click to view Correction: https://doi.org/10.1038/s41417-022-00565-z
-
Authors
Proaño-Pérez, Elizabeth http://orcid.org/0000-0002-0185-3414
Serrano-Candelas, Eva
García-Valverde, Alfonso
Rosell, Jordi
Gómez-Peregrina, David
Navinés-Ferrer, Arnau
Guerrero, Mario
Serrano, César http://orcid.org/0000-0003-1416-8739
Martín, Margarita http://orcid.org/0000-0002-9245-4899
-
Funding
Funding for this research was provided by:
Ministry of Economy and Competitiveness | Agencia Estatal de Investigación (RTI2018-096915-B100, PID2021-122898OB-100)
Spanish Ministry of Science, Innovation, and Universities and European Regional Fund/ European Social Fund " Investing in your future
Spanish Ministry of Health
- License Information
-
More Information
Article History
Received: 15 June 2022
Revised: 30 August 2022
Accepted: 12 September 2022
First Online: 14 October 2022
Change Date: 18 November 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41417-022-00565-z
Competing interests
: C.S. has received research funding (institution) from Karyopharm, Pfizer, Inc, Deciphera Pharmaceuticals, and Bayer AG; consulting fees (advisory role) from CogentBio, Immunicum AB, Deciphera Pharmaceuticals, and Blueprint Medicines; payment for lectures from PharmaMar, Bayer AG and Blueprint Medicines; and travel grants from PharmaMar, Pfizer, Bayer AG, Novartis, and Lilly. The remaining authors have declared that no conflict of interest exists.
